Beyond Biology: Assessing the Effectiveness and Limitations of SSRIs in Major Depressive Disorder
DOI:
https://doi.org/10.61173/7jjbej33Keywords:
Major Depressive Disorder, Selective Serotonin Reuptake Inhibitors, Cognitive Therapy, Combined TreatmentAbstract
Major depressive disorder (MDD) is a complex condition influenced by biological, genetic, and environmental factors. Selective serotonin reuptake inhibitors (SSRIs) remain one of the most commonly prescribed treatments because of their effectiveness and safety. Research shows that SSRIs significantly reduce depressive symptoms and help prevent relapse when taken consistently. However, since they mainly act on serotonin regulation, their impact is limited to the biological side of depression and does not fully address environmental or cognitive influences. Genetic studies, such as those examining the 5-HTTLPR polymorphism, further suggest that individual differences can affect treatment outcomes. Cognitive therapy (CT), on the other hand, focuses on identifying and changing negative thought patterns that often lead to relapse. When combined, antidepressant medication (ADM) and CT provide both immediate symptom relief and more lasting recovery. ADM stabilizes brain chemistry, while CT helps patients build psychological resilience. This integrated approach not only reduces relapse rates but also addresses the broader causes of depression. Overall, combining pharmacological and psychological treatments offers a more balanced and comprehensive strategy for managing MDD and improving long-term mental health outcomes.
References
American Psychological Association. (2020). Depression treatments for adults. APA. https://www.apa.org/depression-guideline/adults
Bhar, S. S., et al. (2008). Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapy. Journal of Affective Disorders, 110(1–2), 161–168.
DeLucia, V., Kelsberg, G., & Safranek, S. (2016). Which SSRIs most effectively treat depression in adolescents? Journal of Family Practice, 65(9), 632–634.
Feighner, J. P. (1999). Mechanism of action of antidepressant medications. Journal of Clinical Psychiatry, 60(Suppl 4), 4–11; discussion 12–13.
Furukawa, T. A., Cipriani, A., & Atkinson, L. Z. (2016). Placebo response rates in antidepressant trials: A systematic review of published and unpublished double-blind randomised controlled studies. The Lancet Psychiatry, 3(11), 1059–1066. https://doi.org/10.1016/S2215- 0366(16)30307-8
Hollon, S. D., Thase, M. E., & Markowitz, J. C. (2002). Treatment and prevention of depression. Psychological Science in the Public Interest, 3(2), 39–77.
Hollon, S. D., et al. (2005). Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Archives of General Psychiatry, 62(4), 417–422.
Malhi, G. S., & Mann, J. J. (2018). Depression. The Lancet, 392(10161), 2299–2312.
McGuffin, P., Alsabban, S., & Uher, R. (2011). The truth about genetic variation in the serotonin transporter gene and response to stress and medication. The British Journal of Psychiatry, 198(6), 424–427.
Nanni, V., Uher, R., & Danese, A. (2012). Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: A meta-analysis. American Journal of Psychiatry, 169(2), 141–151. Wendland, J. R., Martin, B. J., Kruse, M. R., Lesch, K.
P., & Murphy, D. L. (2006). Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Molecular Psychiatry, 11(3), 224–226.
Wong, M. L., Dong, C., & Flores, D. L. (2014). [Title missing]. American Journal of Psychiatry, 171(12), 1297– 1309.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
